These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20799878)

  • 41. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
    Rowinsky EK
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinically relevant cancer biomarkers and pharmacogenetic assays.
    Patel JN; Mandock K; McLeod HL
    J Oncol Pharm Pract; 2014 Feb; 20(1):65-72. PubMed ID: 23353710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
    Le Tourneau C; Diéras V; Tresca P; Cacheux W; Paoletti X
    Target Oncol; 2010 Mar; 5(1):65-72. PubMed ID: 20361265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Veterinary oncology clinical trials: design and implementation.
    Thamm DH; Vail DM
    Vet J; 2015 Aug; 205(2):226-32. PubMed ID: 25582798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
    Harrington JA; Hernandez-Guerrero TC; Basu B
    Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trial designs incorporating predictive biomarkers.
    Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
    Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics: biological activity of targeted therapies in clinical trials.
    Rojo F; Dalmases A; Corominas JM; Albanell J
    Clin Transl Oncol; 2007 Oct; 9(10):634-44. PubMed ID: 17974524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using "rationally designed drugs" rationally.
    Brugarolas J; Clark JW; Chabner B
    Lancet; 2003 May; 361(9371):1758-9. PubMed ID: 12781531
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel agents: clinical trial design.
    Tan AR; Swain SM
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):148-53. PubMed ID: 11706406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.
    Kummar S; Do K; Coyne GO; Chen A; Ji J; Rubinstein L; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):446-52. PubMed ID: 27663476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
    Yamazaki S; Spilker ME; Vicini P
    Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
    Schmidt C
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.
    Zhang Y; Doshi S; Zhu M
    Br J Clin Pharmacol; 2015 Nov; 80(5):957-64. PubMed ID: 25912961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Managing Expectations in the Transition to Proof of Concept Studies.
    Kieber-Emmons T; Makhoul I; Pennisi A; Siegel ER; Emanuel PD; Monzavi-Karbassi B; Steplewski Z; Beck JT; Hutchins LF
    Rev Recent Clin Trials; 2017; 12(2):111-123. PubMed ID: 28325150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Phase 0 trials in drug development.
    Doroshow JH; Kummar S
    Future Med Chem; 2009 Nov; 1(8):1375-80. PubMed ID: 21426052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Compressing drug development timelines in oncology using phase '0' trials.
    Kummar S; Kinders R; Rubinstein L; Parchment RE; Murgo AJ; Collins J; Pickeral O; Low J; Steinberg SM; Gutierrez M; Yang S; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
    Nat Rev Cancer; 2007 Feb; 7(2):131-9. PubMed ID: 17251919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Innovations in Clinical Trial Design in the Era of Molecular Profiling.
    Wulfkuhle JD; Spira A; Edmiston KH; Petricoin EF
    Methods Mol Biol; 2017; 1606():19-36. PubMed ID: 28501991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.